Recombinant Human PSENEN Protein，His

PSENEN (Presenilin Enhancer 2) is a crucial protein involved in the processing of amyloid precursor protein (APP), which is significant in the pathogenesis of Alzheimer’s disease. As a part of the gamma-secretase complex, PSENEN is responsible for the cleavage of APP, leading to the production of amyloid-beta peptides that aggregate into plaques, a hallmark of Alzheimer’s pathology. Mutations in PSENEN, alongside other components of the gamma-secretase complex, have been linked to familial forms of Alzheimer's disease, highlighting its essential role in neuronal integrity and function. Research on PSENEN has gained momentum due to its potential as a therapeutic target; understanding its structure and functional mechanisms could pave the way for innovative strategies in Alzheimer's treatment. Moreover, recombinant PSENEN protein is instrumental for in vitro studies, allowing researchers to dissect the biochemical pathways involved in gamma-secretase activity and identify new modulators that could influence the aberrant processing of APP. By elucidating the role of PSENEN in amyloidogenesis, researchers aim to contribute to the broader understanding of Alzheimer’s disease and explore the development of novel interventions that may slow down or halt the progression of this debilitating condition. Studies utilizing recombinant PSENEN also facilitate the investigation of protein-protein interactions and the exploration of PSENEN's influence in other cellular processes, further emphasizing its importance in neurobiology and potential as a biomarker for disease progression. The ongoing research endeavors aim to provide insights that are critical for the advancement of therapeutic approaches targeting the underlying mechanisms of Alzheimer’s disease.